Honoring Visionary Leadership in Hemophilia Care: A Tribute to Drs. Cesar Garrido and Assad Haffar
Heghine Khachatryan, Head of Hemophilia and Thrombosis Center, Yeolyan Hematology and Oncology Center, recently shared a praising post on LinkedIn:
”This entire initiative was made possible through the leadership of Dr. Assad Haffar, our deeply respected and beloved mentor. His unwavering commitment to advancing clinical quality, medical education, equitable access to diagnosis and care, and global humanitarian support continues to inspire all of us.
Dr. Haffar’s visionary guidance and tireless dedication have shaped not only national strategies but also individual professional growth, bringing together physicians and treatment centers across regions in a shared mission to improve the lives of people with bleeding disorders.
We were especially honored by the presence of WFH President Cesar Garrido, whose leadership, compassion, and advocacy empower national teams and patient communities worldwide. His engagement in these discussions reaffirmed the importance of solidarity, inclusiveness, and sustained investment in care.
We are truly grateful for his mentorship and trust.”
More insights featured in Hemostasis Today.
-
Aug 4, 2025, 17:06Nathan Connell and John Fanikos Invite You to the Vasculearn Network Podcast
-
Aug 4, 2025, 16:44Honoring Visionary Leadership in Hemophilia Care: A Tribute to Drs. Cesar Garrido and Assad Haffar
-
Aug 4, 2025, 14:54Shreyas Kalantri: Engaging Insights on VTE Management
-
Aug 4, 2025, 06:00Genotype–Phenotype Understanding in Hemophilia B: Commentary on Factor IX Missense Variants
-
Aug 4, 2025, 05:47National Health Center Week – Recognizing the Vital Role of HTCs in Specialized Care
-
Aug 4, 2025, 17:29MADD: First Causal Gene for Quantitative Von Willebrand Disease Discovered
-
Aug 4, 2025, 16:13Nicolas Gendron on TITAN’s Recent Study: Insights on Managing Pregnancy in Antithrombin Deficiency
-
Aug 4, 2025, 01:59Michael Makris Posts Haemophilia Journal Article Reassessing UK Blood Inquiry
-
Aug 4, 2025, 01:09Manuel Monreal Congratulates Authors Ahead of JTH Publication: VTE-Predict Score Validated in RIETE Cohort
-
Aug 3, 2025, 17:48Nathan Connell: What Is The "Mild Equivalent" For Hemophilia A That Is Achieved While on Emicizumab?
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 4, 2025, 05:20NBCA: Alexis’s DVT Diagnosis Came Without Warning - Learn How She Caught It Early
-
Aug 4, 2025, 00:50NBCA: After Losing Her Daughter to a Blood Clot, Charita Fights to Save Others
-
Aug 3, 2025, 18:10Andrew Agwunobi Congrats Dr. Oladipo Cole and The Whole Team at the Connecticut Bleeding Disorder Center
-
Aug 3, 2025, 12:03Elias Bouchi Presents Werfen EEMEA Talks on Hemostasis: Clot Stories Season 3
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab